Clinical trials

A double-blind, placebo-controlled intervention trial, where Diamyd^® (GAD-alum) is administered directly into lymph nodes in combination with vitamin D. The trial evaluates the effectiveness of preserving the insulin producing capacity. This trial is conducted in four countries: Sweden, Spain, the Czech Republic and the Netherlands .

• 106 participants
• 12-24 years
• 15 mth duration

An open label intervention trial, where Diamyd^® is administered directly into lymph nodes in combination with vitamin D. The aim of the trial is to evaluate the safety of the combination treatment and the effect on the immune system and the patients’ insulin producing capacity.

• 12 participants
• 12-30 years
• 30 mth duration

An open label investigator initiated intervention trial with oral treatment of Remygen^®. The aim of the trial is to evaluate the safety of the treatment and the effect on the ability to regenerate insulin-producing beta cells. The trial starts in 2018.

• 30 participants
• 18-50 years
• 9 mth duration

A placebo-controlled intervention trial where Diamyd^® is combined with GABA. The aim of the combination treatment is to preserve the body’s residual capacity to produce insulin.

• 95 participants
• 4-18 years
• 12 mth duration

An open label intervention trial where Diamyd^® is combined with etanercept and vitamin D. The aim of the trial is to evaluate the safety of the combination treatment and the effect on the immune system and the patient’s insulin producing capacity.

• 20 participants
• 8-18 years
• 30 mth duration

A placebo-controlled prevention trial where Diamyd^®, in combination with vitamin D, is administered to children at high risk of developing type 1 diabetes, meaning that they have an ongoing autoimmune process but not yet any clinical symptoms of diabetes. The aim of the trial is to evaluate whether Diamyd^® can delay or prevent the participants from presenting with type 1 diabetes.

• 26 participants
• 4-18 years
• 24 mth duration